A novel nutritional supplement containing amino acids and chromium decreases postprandial glucose response in a randomized, double-blind, placebo-controlled study.

What Was Tested

Researchers studied Copper (Supplement) in this randomized controlled trial publication.

The primary endpoint was the incremental area under the curve (iAUC) for venous blood glucose from 0 to 120 minutes.

Secondary endpoints included glucose iAUC 0-180 minutes and the maximum glucose concentration (Cmax), for both venous and capillary blood glucose.

Who Took Part

The age groups tagged for this paper are teenagers, young adults, adults and middle-aged adults, both men and women.

Sixty overweight healthy male and female participants were recruited at two centers and randomized in a double-blind, placebo-controlled, crossover design.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and crossover study.

The participants were allocated by chance, so the Copper (Supplement) group and the comparison group should start out alike.

Blinding on both sides kept the participants and researchers unaware of who received Copper (Supplement).

The comparison arm used a placebo, so changes seen with Copper (Supplement) could be set against what happens without it.

Each person switched between Copper (Supplement) and the comparison at some point, usually with a gap in between.

What Was Measured

The primary endpoint was the incremental area under the curve (iAUC) for venous blood glucose from 0 to 120 minutes.

Secondary endpoints included glucose iAUC 0-180 minutes and the maximum glucose concentration (Cmax), for both venous and capillary blood glucose.

The subject headings attached to it are Amino Acids, Chromium, Dietary Supplements, Glucose and Postprandial Period.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Copper (Supplement).

The publication is from 2020 (PloS one), a journal based in United States.

More context: the Copper (Supplement) compound page, all human trials.